Amarin receives US patent for Vascepa

Amarin Corporation plc, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, has announced that the US Patent and Trademark Office, or USPTO, has issued a patent covering Amarin's Vascepa, or icosapent ethyl, capsules based on US Patent Application Serial No. 13/282,145.

On September 4, 2012, Amarin announced the issuance of a Notice of Allowance for claims under this application. The newly issued patent, US Patent No. 8,318,715, has a term that expires no earlier than in 2030. Amarin plans to list this patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book.

"This patent issuance represents yet another step forward in Amarin's effort to protect the commercial potential of Vascepa," said Joseph Zakrzewski, Amarin's Chairman and CEO. "Amarin's goal is to protect the commercial potential of Vascepa to beyond 2030 through patent protection, regulatory exclusivity and trade secrets and by taking advantage of manufacturing barriers to entry."